Cargando…
EUFOREA consensus on biologics for CRSwNP with or without asthma
Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of pati...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/ https://www.ncbi.nlm.nih.gov/pubmed/31090937 http://dx.doi.org/10.1111/all.13875 |
_version_ | 1783489949743448064 |
---|---|
author | Fokkens, Wytske J. Lund, Valerie Bachert, Claus Mullol, Joaquim Bjermer, Leif Bousquet, Jean Canonica, Giorgio W. Deneyer, Lauren Desrosiers, Martin Diamant, Zuzana Han, Joseph Heffler, Enrico Hopkins, Claire Jankowski, Roger Joos, Guy Knill, Andrew Lee, Jivianne Lee, Stella E. Mariën, Gert Pugin, Benoit Senior, Brent Seys, Sven F. Hellings, Peter W. |
author_facet | Fokkens, Wytske J. Lund, Valerie Bachert, Claus Mullol, Joaquim Bjermer, Leif Bousquet, Jean Canonica, Giorgio W. Deneyer, Lauren Desrosiers, Martin Diamant, Zuzana Han, Joseph Heffler, Enrico Hopkins, Claire Jankowski, Roger Joos, Guy Knill, Andrew Lee, Jivianne Lee, Stella E. Mariën, Gert Pugin, Benoit Senior, Brent Seys, Sven F. Hellings, Peter W. |
author_sort | Fokkens, Wytske J. |
collection | PubMed |
description | Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma. |
format | Online Article Text |
id | pubmed-6972984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69729842020-01-27 EUFOREA consensus on biologics for CRSwNP with or without asthma Fokkens, Wytske J. Lund, Valerie Bachert, Claus Mullol, Joaquim Bjermer, Leif Bousquet, Jean Canonica, Giorgio W. Deneyer, Lauren Desrosiers, Martin Diamant, Zuzana Han, Joseph Heffler, Enrico Hopkins, Claire Jankowski, Roger Joos, Guy Knill, Andrew Lee, Jivianne Lee, Stella E. Mariën, Gert Pugin, Benoit Senior, Brent Seys, Sven F. Hellings, Peter W. Allergy Reviews Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma. John Wiley and Sons Inc. 2019-07-15 2019-12 /pmc/articles/PMC6972984/ /pubmed/31090937 http://dx.doi.org/10.1111/all.13875 Text en © 2019 The Authors Allergy Published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Fokkens, Wytske J. Lund, Valerie Bachert, Claus Mullol, Joaquim Bjermer, Leif Bousquet, Jean Canonica, Giorgio W. Deneyer, Lauren Desrosiers, Martin Diamant, Zuzana Han, Joseph Heffler, Enrico Hopkins, Claire Jankowski, Roger Joos, Guy Knill, Andrew Lee, Jivianne Lee, Stella E. Mariën, Gert Pugin, Benoit Senior, Brent Seys, Sven F. Hellings, Peter W. EUFOREA consensus on biologics for CRSwNP with or without asthma |
title | EUFOREA consensus on biologics for CRSwNP with or without asthma |
title_full | EUFOREA consensus on biologics for CRSwNP with or without asthma |
title_fullStr | EUFOREA consensus on biologics for CRSwNP with or without asthma |
title_full_unstemmed | EUFOREA consensus on biologics for CRSwNP with or without asthma |
title_short | EUFOREA consensus on biologics for CRSwNP with or without asthma |
title_sort | euforea consensus on biologics for crswnp with or without asthma |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972984/ https://www.ncbi.nlm.nih.gov/pubmed/31090937 http://dx.doi.org/10.1111/all.13875 |
work_keys_str_mv | AT fokkenswytskej euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT lundvalerie euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT bachertclaus euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT mulloljoaquim euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT bjermerleif euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT bousquetjean euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT canonicagiorgiow euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT deneyerlauren euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT desrosiersmartin euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT diamantzuzana euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT hanjoseph euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT hefflerenrico euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT hopkinsclaire euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT jankowskiroger euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT joosguy euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT knillandrew euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT leejivianne euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT leestellae euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT mariengert euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT puginbenoit euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT seniorbrent euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT seyssvenf euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma AT hellingspeterw euforeaconsensusonbiologicsforcrswnpwithorwithoutasthma |